• Proud to Support APHCA as a Platinum Presenting Sponsor

    Chief Operating Officer Tim Vroman and the RxStrategies team are pleased to network and connect with industry leaders during the APHCA Annual Conference in Mobile, Alabama, from September 20-22. We are especially proud to support the efforts of APHCA to strengthen health center network and improved access to primary care and coordinated services in communities… Read more »

  • Clinical Insights — August 2016 Issue

    Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Adlyxin™ (lixisenatide) – July 28, 2016 – The U.S. Food and Drug Administration approved Adlyxin™ (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with… Read more »

  • Celebrating America’s Health Centers

          National Health Center Week has been celebrated for more than 30 years to recognize the services and contributions of Community Health Centers. While there are countless reasons to celebrate America’s Health Centers, among the most important and unique is their long success in providing access to affordable, high quality, cost effective health care to medically… Read more »

  • Join RxStrategies at the FACHC 2016 Annual Meeting

    Fenton Markevich and the RxStrategies team will be meeting with industry leaders during Florida Association of Community Health Centers 2016 Annual Meeting and Educational Summit.This year’s conference will take place July 31 – August 3, in Fort Lauderdale. Learn more about the conference here. We are looking forward to discussing integrated 340B program management solutions… Read more »

  • 340B INSIDER – July 2016

    Welcome to the July edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   UPDATES FROM THE 340B COALITION SUMMER CONFERENCE   CONFERENCE HIGHLIGHTS RxStrategies’ Increased Presence at 340B Coalition Summer Conference It was great to connect with so many industry leaders during the conference. Thank you… Read more »

  • Adventist Health and RxStrategies, Inc. Agree to Extend its 340B Management Agreement

    Adventist Health and RxStrategies, Inc. have agreed to continue the 340B program management agreement for an additional three years, the companies announced today. The agreement covers all of the participating sites for Adventist Health in the western states of California, Hawaii, Oregon and Washington. The agreement continues the relationship first established in 2012 between the… Read more »

  • Clinical Insights — April 2016 Issue

    Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Venclexta™ (venetoclax) April 11, 2016 – The U.S. Food and Drug Administration approved Venclexta™ (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who… Read more »

  • Todd Hudnall Joins the Team

    RxStrategies, Inc. is pleased to announce the appointment of Todd Hudnall to the new position of Sales Manager – Midwest Region. He joins the RxStrategies sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the Midwest Region. “I am very pleased to… Read more »

  • 340B Insider – March 2016

    Welcome to the March edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B UNIVERSITY UPDATES Recently, the RxStrategies experts attended 340B University, presented by Apexus, to gain further insight regarding current 340B trends.  The following are highlights from a recent session: 1.) 340B Mega Guidance: Over 1300… Read more »